dmard < dmards < dna

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 58.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000008 (2010)	P. Roll [Allemagne] ; A. Rubbert-Roth [Allemagne] ; H.-P. Tony [Allemagne]	Tocilizumab
000015 (2013)	Jörg Kaufmann [Allemagne] ; Eugen Feist [Allemagne] ; Anne-Eve Roske [Allemagne] ; Wolfgang A. Schmidt [Allemagne]	Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice
000016 (2009)	Mao Mao An [République populaire de Chine] ; Zui Zou [République populaire de Chine] ; Hui Shen [République populaire de Chine] ; Jun Dong Zhang [République populaire de Chine] ; Yong Bing Cao [République populaire de Chine] ; Yuan Ying Jiang [République populaire de Chine]	The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials
000020 (2011)	Taras Gout [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni]	Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
000025 (2014)	Shuji Ohta [Japon] ; Tomomi Tsuru [Japon] ; Kimio Terao [Japon] ; Seiji Mogi [Japon] ; Midori Suzaki [Japon] ; Eisuke Shono [Japon] ; Yoshimasa Ishida [Japon] ; Eriko Tarumi [Japon] ; Masato Imai [Japon]	Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)
000035 (2013)	T. Witte [Allemagne]	Methotrexat als Kombinationspartner bei TNF-Inhibitoren und Tocilizumab
000050 (2011)	Masaaki Hiura [Japon] ; Shintaro Abe ; Akinari Tabaru ; Shohei Shimajiri ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Masaru Harada	Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis
000059 (2012)	Kevin Kwan [Australie] ; Sneha Bharadwaj [Australie] ; Charles Inderjeeth [Australie]	Response to treatment with tocilizumab of reactive arthritis induced by intravesical bacillus Galmette‐Guérin unresponsive to DMARDs
000080 (2012)	M. Licht [Allemagne] ; U. Kyank [Allemagne] ; C. Kneitz [Allemagne]	Therapierefraktäre Polyarthritis und Fieber
000088 (2011)	Emily Beth Devine [États-Unis] ; Rafael Alfonso-Cristancho [États-Unis] ; Sean D. Sullivan [États-Unis]	Effectiveness of Biologic Therapies for Rheumatoid Arthritis: An Indirect Comparisons Approach
000094 (2011)	Maasa Hama [Japon] ; Takeaki Uehara [Japon] ; Kaoru Takase [Japon] ; Atsushi Ihata [Japon] ; Atsuhisa Ueda [Japon] ; Mitsuhiro Takeno [Japon] ; Kazuya Shizukuishi [Japon] ; Ukihide Tateishi [Japon] ; Yoshiaki Ishigatsubo [Japon]	Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab—preliminary data
000099 (2010)	Chi Chiu Mok [Hong Kong] ; Lai Shan Tam [Hong Kong] ; Tak Hin Chan [Hong Kong] ; Gavin K. W. Lee [Hong Kong] ; Edmund K. M. Li [Hong Kong]	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology
000105 (2012)	M. Gallego-Galisteo ; A. Villa-Rubio ; E. Alegre-Del Rey [Espagne] ; E. Márquez-Fernández ; J. J. Ramos-Báez	Indirect comparison of biological treatments in refractory rheumatoid arthritis
000133 (2009)	Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami [Japon] ; Satoshi Yamasaki [Japon] ; Takahiro Imazato [Japon] ; Naoki Iwamoto [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Hiroaki Ida [Japon] ; Tomoki Origuchi [Japon] ; Yukitaka Ueki [Japon] ; Katsumi Eguchi [Japon]	Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
000146 (2010)	G. Horneff [Allemagne]	Juvenile Arthritiden
000150 (2012)	O. Psenak [Autriche] ; A. Studnicka-Benke [Autriche] ; R. Greil [Autriche]	Sicherheit der Immunsuppressiva
000154 (2011)	Atsushi Kaneko [Japon] ; Daihei Kida [Japon] ; Kiwamu Saito [Japon] ; Masami Tsukamoto [Japon] ; Tomotaro Sato [Japon]	Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI
000178 (2010)	G. Dückers [Allemagne] ; T. Niehues [Allemagne]	Die Bedeutung von Biologika bei der Therapie der SoJIA (Morbus Still)
000203 (2011)	K. Krüger [Allemagne]	Kombinationsbehandlung von Methotrexat mit DMARDs oder Biologika – Aktueller Stand
000249 (2010)	R. E. Fischer-Betz [Allemagne] ; M. Schneider [Allemagne]	Biologika in Schwangerschaft und Stillzeit
000251 (2006)	Chi Chiu Mok [Hong Kong]	Biological therapies for rheumatoid arthritis: beyond TNF‐α blockade

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "dmards" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "dmards" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    dmards
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021